April 16, 2026
Losing touch with reality
Listening to the earnings call for Abbott this morning it’s becoming obvious that both the company and the analysts who cover the company are losing touch with reality when it comes to the Libre franchise. As we anticipated growth in CGM is slowing which really is no surprise. This is not news.
CGM is following almost the exact same path as BGM did. In the beginning intensive insulin patients were the low hanging fruit for CGM adoption. With that market segment successfully penetrated the next level is Type 2 basal only patients . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
